Risankizumab as a promising therapeutic approach in obese patients

Obesity and increased waist circumference are associated with all the factors constituting the metabolic syndrome (type 2 diabetes, sleep apnea, hypertension, dyslipidaemia, acute myocardial infarction…) and also with an increased mortality. One of the main methods to determine the obesity is through the body mass index (BMI), which is calculated as weight in kilograms, divided by height in metres squared. Obesity is considered to be when the BMI is greater than 30 kg/m². The association with psoriasis has been revealed in different epidemiological studies and clinical trials and mainly affects patients who develop more severe forms of psoriasis. We report an obese patient under treatment with Risankizumab with successful and sustained response over 52 weeks, as a very promising therapeutic approach as an efficient treatment in this patients